Leerink raised the firm’s price target on NeoGenomics (NEO) to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving “beatable guidance and realistic targets,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism
- NeoGenomics’ Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating
- NeoGenomics reports Q3 adjusted EPS 3c, consensus 2c
- NeoGenomics backs FY25 revenue view $720M-$726M, consensus $722.46M
- NEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?